AAAAAA

   
Results: 1-25 | 26-47
Results: 1-25/47
EX-VIVO EXPANSION OF BONE-MARROW CELLS FOR HEMATOPOIETIC RECONSTITUTION FOLLOWING HIGH-DOSE CHEMOTHERAPY FOR BREAST-CANCER
Authors: BACHIER C GOKMEN E TEALE J LANZKRON S HOUGHAM M MENEGHETTI C NANEZ A HUERTA J CHILDS C FRANKLIN W DOUVILLE J WEBER S ARMSTRONG D LEMAISTRE CF
Citation: C. Bachier et al., EX-VIVO EXPANSION OF BONE-MARROW CELLS FOR HEMATOPOIETIC RECONSTITUTION FOLLOWING HIGH-DOSE CHEMOTHERAPY FOR BREAST-CANCER, Experimental hematology, 26(8), 1998, pp. 67-67
EMPIRICAL CRITERIA FOR THE SELECTION OF QUALITY-OF-LIFE INSTRUMENTS FOR THE EVALUATION OF PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION
Authors: GLICK HA SHPALL EJ LEMAISTRE CF MCCARRON TJ LU ZJ ERDER MH GLASPY JA
Citation: Ha. Glick et al., EMPIRICAL CRITERIA FOR THE SELECTION OF QUALITY-OF-LIFE INSTRUMENTS FOR THE EVALUATION OF PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION, International journal of technology assessment in health care, 14(3), 1998, pp. 419-430
ANTITUMOR-ACTIVITY OF DAB(389)IL-2 FUSION TOXIN IN MYCOSIS-FUNGOIDES
Authors: SALEH MN LEMAISTRE CF KUZEL TM FOSS F PLATANIAS LC SCHWARTZ G RATAIN M ROOK A FREYTES CO CRAIG F REUBEN J SAMS MW NICHOLS JC
Citation: Mn. Saleh et al., ANTITUMOR-ACTIVITY OF DAB(389)IL-2 FUSION TOXIN IN MYCOSIS-FUNGOIDES, Journal of the American Academy of Dermatology, 39(1), 1998, pp. 63-73
PBPC MOBILIZATION - THE BENEFITS OF STEM-CELL FACTOR (SCF, STEMGEN(R)) AND AN OPTIMAL CD34(+) CELL YIELD
Authors: LEMAISTRE CF SHPALL EJ TURNER SA WHEELER CA YANOVICH S BROWN RA PECORA AL DAVIS MW PARKER W GLASPY JA
Citation: Cf. Lemaistre et al., PBPC MOBILIZATION - THE BENEFITS OF STEM-CELL FACTOR (SCF, STEMGEN(R)) AND AN OPTIMAL CD34(+) CELL YIELD, British Journal of Haematology, 102(1), 1998, pp. 152-152
PHASE-I TRIAL OF A LIGAND FUSION-PROTEIN (DAB(389)IL-2) IN LYMPHOMAS EXPRESSING THE RECEPTOR FOR INTERLEUKIN-2
Authors: LEMAISTRE CF SALEH MN KUZEL TM FOSS F PLATANIAS LC SCHWARTZ G RATAIN M ROOK A FREYTES CO CRAIG F REUBEN J NICHOLS JC
Citation: Cf. Lemaistre et al., PHASE-I TRIAL OF A LIGAND FUSION-PROTEIN (DAB(389)IL-2) IN LYMPHOMAS EXPRESSING THE RECEPTOR FOR INTERLEUKIN-2, Blood, 91(2), 1998, pp. 399-405
FOUNDATION FOR THE ACCREDITATION OF HEMATOPOIETIC-CELL THERAPY (FAHCT) RESPONSE TO FDA (DOCKET NO.97N-0068)
Authors: SHPALL EJ CHAMPLIN RE EAVES AC GEE AP COLLINS N LEMAISTRE CF OREILLY R ROWLEY SD SULLIVAN K VAUGHAN WP WARKENTIN PL
Citation: Ej. Shpall et al., FOUNDATION FOR THE ACCREDITATION OF HEMATOPOIETIC-CELL THERAPY (FAHCT) RESPONSE TO FDA (DOCKET NO.97N-0068), Journal of hematotherapy, 6(4), 1997, pp. 287-289
INTERLEUKIN-2 FUSION PROTEIN - AN INVESTIGATIONAL THERAPY FOR INTERLEUKIN-2 RECEPTOR-EXPRESSING MALIGNANCIES
Authors: NICHOLS J FOSS F KUZEL TM LEMAISTRE CF PLATANIAS L RATAIN MJ ROOK A SALEH M SCHWARTZ G
Citation: J. Nichols et al., INTERLEUKIN-2 FUSION PROTEIN - AN INVESTIGATIONAL THERAPY FOR INTERLEUKIN-2 RECEPTOR-EXPRESSING MALIGNANCIES, European journal of cancer, 33, 1997, pp. 34-36
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR INTERLEUKIN-3 FUSIONPROTEIN VERSUS GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AFTERAUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR NON-HODGKINS-LYMPHOMA - RESULTS OF A RANDOMIZED DOUBLE-BLIND TRIAL
Authors: VOSE JM PANDITE AN BEVERIDGE RA GELLER RB SCHUSTER MW ANDERSON JE LEMAISTRE CF AHMED T GRANENA A KEATING A RANADA JMF STIFF PJ TABBARA I LONGO W COPELAN EA NICHOLS C SMITH A TOPOLSKY DL BIERMAN PJ LEBSACK ME LANGE M GARRISON L
Citation: Jm. Vose et al., GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR INTERLEUKIN-3 FUSIONPROTEIN VERSUS GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AFTERAUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR NON-HODGKINS-LYMPHOMA - RESULTS OF A RANDOMIZED DOUBLE-BLIND TRIAL, Journal of clinical oncology, 15(4), 1997, pp. 1617-1623
USE OF STEM-CELL FACTOR PLUS FILGRASTIM IMPROVES PBPC COLLECTION IN HEAVILY PRETREATED PATIENTS WITH LYMPHOMA OR HODGKINS-DISEASE
Authors: STIFF P EMMANOUILIDES C LUGER S HARMAN G LEMAISTRE CF BROWN R PERRY J MASON JR LIST A BENSINGER W FRETER D SCHENKEIN D BRANNAN C OLSON E WYRES M WHEELER C
Citation: P. Stiff et al., USE OF STEM-CELL FACTOR PLUS FILGRASTIM IMPROVES PBPC COLLECTION IN HEAVILY PRETREATED PATIENTS WITH LYMPHOMA OR HODGKINS-DISEASE, Experimental hematology, 25(8), 1997, pp. 359-359
PERIPHERAL-BLOOD PROGENITOR-CELL MOBILIZATION USING STEM-CELL FACTOR IN COMBINATION WITH FILGRASTIM IN BREAST-CANCER PATIENTS
Authors: GLASPY JA SHPALL EJ LEMAISTRE CF BRIDDELL RA MENCHACA DM TURNER SA LILL M CHAP L JONES R WIERS MD SHERIDAN WP MCNIECE IK
Citation: Ja. Glaspy et al., PERIPHERAL-BLOOD PROGENITOR-CELL MOBILIZATION USING STEM-CELL FACTOR IN COMBINATION WITH FILGRASTIM IN BREAST-CANCER PATIENTS, Blood, 90(8), 1997, pp. 2939-2951
A PROSPECTIVE RANDOMIZED TRIAL OF BUFFY COAT VERSUS CD34-SELECTED AUTOLOGOUS BONE-MARROW SUPPORT IN HIGH-RISK BREAST-CANCER PATIENTS RECEIVING HIGH-DOSE CHEMOTHERAPY
Authors: SHPALL EJ LEMAISTRE CF HOLLAND K BALL E JONES RB SARAL R JACOBS C HEIMFELD S BERENSON R CHAMPLIN R
Citation: Ej. Shpall et al., A PROSPECTIVE RANDOMIZED TRIAL OF BUFFY COAT VERSUS CD34-SELECTED AUTOLOGOUS BONE-MARROW SUPPORT IN HIGH-RISK BREAST-CANCER PATIENTS RECEIVING HIGH-DOSE CHEMOTHERAPY, Blood, 90(11), 1997, pp. 4313-4320
INCIDENCE OF GRAFT VS. HOST-DISEASE IN PATIENTS UNDERGOING ALLOGENEICPERIPHERAL-BLOOD STEM-CELL TRANSPLANTS OR BONE-MARROW TRANSPLANTS ON CYCLOSPORINE AND STEROID PROPHYLAXIS
Authors: LANZKRON S BACHIER C ALEXANDER L MENEGHETTI C NANEZ A BOTELLO J HUERTA J CHILDS C LEMAISTRE CF
Citation: S. Lanzkron et al., INCIDENCE OF GRAFT VS. HOST-DISEASE IN PATIENTS UNDERGOING ALLOGENEICPERIPHERAL-BLOOD STEM-CELL TRANSPLANTS OR BONE-MARROW TRANSPLANTS ON CYCLOSPORINE AND STEROID PROPHYLAXIS, Blood, 90(10), 1997, pp. 4499-4499
EX-VIVO EXPANSION OF STEM-CELLS (SC) FOR HEMATOPOIETIC RECONSTITUTIONFOLLOWING HIGH-DOSE CHEMOTHERAPY (HDC) FOR BREAST-CANCER
Authors: BACHIER C LANZKRON S HOUGHAM M MENEGHETTI C NANEZ A BOTELLO J HUERTA J SLANHAM S CHILDS C MULLER TE ARMSTRONG RD WEBER S LEMAISTRE CF
Citation: C. Bachier et al., EX-VIVO EXPANSION OF STEM-CELLS (SC) FOR HEMATOPOIETIC RECONSTITUTIONFOLLOWING HIGH-DOSE CHEMOTHERAPY (HDC) FOR BREAST-CANCER, Blood, 90(10), 1997, pp. 1632-1632
B-CELL AND T-CELL OBTAINED FROM EX-VIVO EXPANDED BONE-MARROW (BM) MONONUCLEAR CELL (MNC) TRANSPLANT RECIPIENTS EXHIBIT IG-H AND TCRVB CDR3 REPERTOIRES SIMILAR TO THAT SEEN AFTER CONVENTIONAL HEMATOPOIETIC STEM-CELL TRANSPLANTATION
Authors: GOKMEN E RAAPHORST FM BACHIER C LEMAISTRE CF MULLER TE ARMSTRONG RD BOLDT DH TEALE JM
Citation: E. Gokmen et al., B-CELL AND T-CELL OBTAINED FROM EX-VIVO EXPANDED BONE-MARROW (BM) MONONUCLEAR CELL (MNC) TRANSPLANT RECIPIENTS EXHIBIT IG-H AND TCRVB CDR3 REPERTOIRES SIMILAR TO THAT SEEN AFTER CONVENTIONAL HEMATOPOIETIC STEM-CELL TRANSPLANTATION, Blood, 90(10), 1997, pp. 2403-2403
A RANDOMIZED PHASE-3 STUDY OF PBPC MOBILIZATION BY STEM-CELL FACTOR (SCF, STEMGEN(R)) AND FILGRASTIM IN PATIENTS WITH HIGH-RISK BREAST-CANCER
Authors: SHPALL EJ WHEELER CA TURNER SA YANOVICH S BROWN RA PECORA AL SHEA TC MANGAN KF WILLIAMS SF LEMAISTRE CF LONG GD MURPHYFILKINS R PARKER W GLASPY JA
Citation: Ej. Shpall et al., A RANDOMIZED PHASE-3 STUDY OF PBPC MOBILIZATION BY STEM-CELL FACTOR (SCF, STEMGEN(R)) AND FILGRASTIM IN PATIENTS WITH HIGH-RISK BREAST-CANCER, Blood, 90(10), 1997, pp. 2627-2627
IMPROVED PBPC COLLECTION USING STEMGEN(R) (STEM-CELL FACTOR, SCF) ANDFILGRASTIM (G-CSF) COMPARED TO G-CSF ALONE IN HEAVILY PRETREATED LYMPHOMA (NNL) AND HODGKINS-DISEASE (HD) PATIENTS (PTS)
Authors: STIFF P GINGRICH R LUGER S BROWN RA LEMAISTRE CF PERRY J SCHENKEIN D LIST A MASON JR BENSINGER W WHEELER CA FRETER C MURPHYFILKINS R WYRES M PARKER W EMMANOUILIDES C
Citation: P. Stiff et al., IMPROVED PBPC COLLECTION USING STEMGEN(R) (STEM-CELL FACTOR, SCF) ANDFILGRASTIM (G-CSF) COMPARED TO G-CSF ALONE IN HEAVILY PRETREATED LYMPHOMA (NNL) AND HODGKINS-DISEASE (HD) PATIENTS (PTS), Blood, 90(10), 1997, pp. 2628-2628
AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR POOR-PROGNOSISLOW-GRADE LYMPHOMA
Authors: FREYTES CO VUKELJA S SALZMAN D TSAI T CALLANDER N GOKMEN E RODRIGUEZ T CASTRO J BOLDT D ROODMAN GD HILSENBECK S ADKINS D BACHIER C CRAIG F CLARE N WEISNER A LEMAISTRE CF
Citation: Co. Freytes et al., AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR POOR-PROGNOSISLOW-GRADE LYMPHOMA, Experimental hematology, 24(9), 1996, pp. 629-629
MALIGNANCY-ASSOCIATED PULMONARY VENOOCCLUSIVE DISEASE - REPORT OF A CASE FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION AND REVIEW
Authors: SALZMAN D ADKINS DR CRAIG F FREYTES C LEMAISTRE CF
Citation: D. Salzman et al., MALIGNANCY-ASSOCIATED PULMONARY VENOOCCLUSIVE DISEASE - REPORT OF A CASE FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION AND REVIEW, Bone marrow transplantation, 18(4), 1996, pp. 755-760
TRANSPLANTATION OF POSITIVELY SELECTED CD34-MARROW AND MOBILIZED PERIPHERAL-BLOOD CELLS FROM HAPLOIDENTICAL RELATED DONORS FOR HIGH-RISK HEMATOLOGIC MALIGNANCIES( BONE)
Authors: YEAGER AM ANASETTI C CHAUNCEY T DIPERSIO JF HOLLAND HK LEMAISTRE CF RYBKA W JACOBS CA BENYUNES MC
Citation: Am. Yeager et al., TRANSPLANTATION OF POSITIVELY SELECTED CD34-MARROW AND MOBILIZED PERIPHERAL-BLOOD CELLS FROM HAPLOIDENTICAL RELATED DONORS FOR HIGH-RISK HEMATOLOGIC MALIGNANCIES( BONE), Blood, 88(10), 1996, pp. 3851-3851
RETICULOCYTE HIGH FLUORESCENCE RATIOS (HFR) AS AN EARLIER AND RELIABLE INDICATOR OF BONE-MARROW ENGRAFTMENT
Authors: HUERTA JC DALUZ R NANEZ AG BOTELLO JS NASH LG HASTINGS JI IRISH D OLIVERSEN SL CHILDS CC LEMAISTRE CF
Citation: Jc. Huerta et al., RETICULOCYTE HIGH FLUORESCENCE RATIOS (HFR) AS AN EARLIER AND RELIABLE INDICATOR OF BONE-MARROW ENGRAFTMENT, Blood, 88(10), 1996, pp. 506-506
PROLONGED CLINICAL REMISSION IN PATIENTS (PTS) WITH INFLAMMATORY BOWEL-DISEASE (IBD) AFTER HIGH-DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS BLOOD STEM-CELL TRANSPLANTATION (ABSCT)
Authors: CASTRO J BENTCH HL SMITH L KALTER S BACHIER C MENEGHETTI C MOORE A OLIVERSEN S LEMAISTRE CF
Citation: J. Castro et al., PROLONGED CLINICAL REMISSION IN PATIENTS (PTS) WITH INFLAMMATORY BOWEL-DISEASE (IBD) AFTER HIGH-DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS BLOOD STEM-CELL TRANSPLANTATION (ABSCT), Blood, 88(10), 1996, pp. 519-519
IMMUNOTOXIN THERAPY OF CANCER - RATIONALE FOR DEVELOPMENT AND FUTURE POTENTIAL
Authors: BACHIER CR LEMAISTRE CF
Citation: Cr. Bachier et Cf. Lemaistre, IMMUNOTOXIN THERAPY OF CANCER - RATIONALE FOR DEVELOPMENT AND FUTURE POTENTIAL, CLINICAL IMMUNOTHERAPEUTICS, 3(6), 1995, pp. 450-460
HIGH-DOSE CHEMOTHERAPY WITH BEAC REGIMEN AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR INTERMEDIATE GRADE AND IMMUNOBLASTIC LYMPHOMA - DURABLE COMPLETE REMISSIONS, BUT A HIGH-RATE OF REGIMEN-RELATED TOXICITY
Authors: VANBESIEN K TABOCOFF J RODRIGUEZ M ANDERSSON B MEHRA R PRZEPIORKA D DIMOPOULOS M GIRALT S SUKI S KHOURI I SPITZER G JAGANNATH S DICKE K LEMAISTRE CF DEISSEROTH A CABANILLAS F CHAMPLIN RE
Citation: K. Vanbesien et al., HIGH-DOSE CHEMOTHERAPY WITH BEAC REGIMEN AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR INTERMEDIATE GRADE AND IMMUNOBLASTIC LYMPHOMA - DURABLE COMPLETE REMISSIONS, BUT A HIGH-RATE OF REGIMEN-RELATED TOXICITY, Bone marrow transplantation, 15(4), 1995, pp. 549-555
HIGH-DOSE MELPHALAN ALLOWS DURABLE ENGRAFTMENT OF ALLOGENEIC BONE-MARROW
Authors: VANBESIEN K DEMUYNCK H LEMAISTRE CF BOGAERTS MA CHAMPLIN R
Citation: K. Vanbesien et al., HIGH-DOSE MELPHALAN ALLOWS DURABLE ENGRAFTMENT OF ALLOGENEIC BONE-MARROW, Bone marrow transplantation, 15(2), 1995, pp. 321-323
IMPORTANCE OF CELL DOSE WITH CD34-SELECTED AUTOLOGOUS MARROW TRANSPLANTS - RESULTS OF A CONTROLLED TRIAL
Authors: CHAMPLIN R BALL E HOLLAND K LEMAISTRE CF JACOBS C SHPALL E
Citation: R. Champlin et al., IMPORTANCE OF CELL DOSE WITH CD34-SELECTED AUTOLOGOUS MARROW TRANSPLANTS - RESULTS OF A CONTROLLED TRIAL, Blood, 86(10), 1995, pp. 1159-1159
Risultati: 1-25 | 26-47